Medicine guide
Agenerase
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Amprenavir
- Made by
- Glaxo Group Ltd.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years. Agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). The choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).The benefit of Agenerase boosted with ritonavir has not been demonstrated in PI nave patients (see section 5.1)
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Glaxo Group Ltd. |
|---|---|
| Active substance | Amprenavir |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AE05 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2000-10-20 |
| Last updated by the regulator | 2011-06-21 |
| EMA product number | EMEA/H/C/000264 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).